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Introduction
Post-thrombotic syndrome (PTS) is an important
outcome after venous thromboembolism (VTE), and rec-
ommendations for standardized measurements following
extremity VTE have been published [1,2]. However, the
clinical spectrum of pediatric VTE extends beyond the
extremities in approximately 25–30% of children, and
long-term outcomes after non-extremity VTE have not
been measured. As such outcomes are site-dependent
and the clinical spectrum is heterogeneous, currently
available PTS outcome scales are inadequate for the
measurement.
To address this issue, the Perinatal and Pediatric Hemo-
stasis Subcommittee of the ISTH established a working
group (WG) to make recommendations for uniform defini-
tions of non-extremity VTE outcomes. Although the
original plan was to review the available literature and
develop guidelines, it was realized that there is a paucity of
literature in this area, and recommendations were therefore
developed on the basis of a review of the available
literature and by consensus. The recommendations were
presented at the 60th SSC meeting in Liverpool, 2012, and
a manuscript draft was developed by the WG which was
then circulated to the Subcommittee chairman and subse-
quently revised to incorporate the input.
Overview of WG discussion
Definition and scope of the problem:
The members concurred with the recommendation from
the WG on extremity PTS that the complications follow-
ing non-extremity thrombosis do not fall within the scope
of the definition of typical PTS, and thus the term
‘post-thrombotic sequelae’ was more appropriate for
describing such outcomes [1,2].
Inclusion of the spectrum of sites for non-extremity
thrombosis:
According to the WG, the term ‘non-extremity thrombo-
sis’ should encompass these sites:
• Intra-abdominal:
Renal vein thrombosis (RVT)
Portal vein thrombosis (PVT)
• Pulmonary arterial thrombosis (pulmonary embolism
[PE])
• Central nervous system (CNS): cortical sinus venous
thrombosis (CSVT)
• Rare sites: mesenteric vein thrombosis, pelvic veins
(ovarian or uterine) thrombosis, hepatic vein thrombosis
(Budd–Chiari syndrome [BCS]), and retinal vein
thrombosis
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Inferior and superior vena caval thrombosis is often
associated with extremity thrombosis, and the WG there-
fore recommended that complications after caval throm-
bosis should be included with extremity thrombosis
outcomes. Also, the modified Villalta scale has a provi-
sion to incorporate long-term complications of superior
vena caval thrombosis, and may be used [3]. The WG
also decided to exclude outcomes after CSVT, as a
separate WG will focus on defining outcomes of CNS
thrombosis.
Recommendations for follow-up:
The WG recommended that patients should be followed
at specific time points, with at least annual evaluation
after the thrombotic event. It was also acknowledged that
such evaluations, ideally, should be performed by the
patient’s primary-care physicians. However, as uniform
data on the outcomes are not available, the committee
felt that, until this becomes the standard of care, such
evaluation(s) should preferably be performed by the pri-
mary subspecialty following the organ dysfunction, with
close communication with the primary-care physician and
hematologist.
Features related to specific organ thrombosis
As the clinical manifestations and severity vary widely
according to the site of thrombosis, the WG decided to
recommend organ-specific criteria. The subsequent para-
graphs will discuss the current literature on long-term
outcomes of various organ-specific thromboses, and the
reasoning behind the suggested classification:
Outcomes after neonatal and pediatric RVT
Although isolated cases have been described in older chil-
dren, RVT is most commonly seen in the neonatal age
group. In a large literature review, although the definition
was heterogeneous, irreversible damage was found in
70.6% of the affected kidneys, regardless of whether anti-
coagulant treatment was received [4]. At a median follow-
up of 3.7 years, 20% of the patients developed hyperten-
sion, and 3% of the patients required renal replacement
therapy or renal transplantation. There is a suggestion
from previous studies that renal size and the laterality
(unilateral vs. bilateral) may influence outcome [5]. On
the basis of these data, a risk assignment score for RVT
is suggested that is inexpensive, practical, objective, and
easily available (Table 1). In combination with the risk
assignment score and the estimated glomerular filtration
rate (calculated with the Schwartz formula), outcomes
following RVT and the need for renal replacement
therapy (such dialysis or renal transplantation) should be
noted. It is recommended that patients are assessed at 6-
month intervals after the episode of thrombosis for at
least 5 years.
Outcomes after neonatal or pediatric PVT
PVT is a major cause of portal hypertension (PHT) in
children, accounting for 5–20% of all cases of PHT [6]
(Table 2). In one neonatal study, PHT developed in 3–
7% of cases on follow-up. PHT is usually defined clini-
cally by the presence of a risk factor (e.g. PVT) and evi-
dence of splenomegaly and/or portosystemic collaterals
(e.g. esophageal varices) on abdominal imaging. Ultra-
sound with Doppler is the imaging modality of choice to
provide supportive evidence for the presence of PHT,
although the use of contrast-enhanced computed tomog-
raphy (CT) and magnetic resonance venography has also
been reported [7,8]. As there is no evidence for the
efficacy of treatment for prevention of variceal bleeding
Table 1 Outcomes after pediatric renal vein thrombosis
Recommended timeline: follow every 6 months after the event for
5 years
Diagnosis and severity to be assessed by using a combination of
points (a) and (b) below
(a) Risk assignment score: a cumulative score should be assigned on
the basis of the criteria below, and then be classified as Subclass A
(score ≤ 4) and Subclass B (score > 4)
Score 0 1 2
Laterality Unilateral Bilateral
Renal atrophy None Unilateral Bilateral
Proteinuria (urine
protein/creatinine ratio)
< 0.2 0.2–0.5 > 0.5
Hypertension None Stage I Stage II
(b) CKD staging (I–V) based on the glomerular filtration rate
calculated with the Schwartz formula (see Supporting information
for the reference) and the calculated risk of deterioration based on
the risk assignment score. (Note: chronic kidney disease stage V
denotes the need for renal replacement therapies such as dialysis
and renal transplantation. In such cases, there is no longer a need
to assign the risk assignment score)
Table 2 Outcomes after pediatric portal vein thrombosis (PVT)
Recommended timeline: start screening at 6 months after the event
(if the exact date is not known, then at the point of first detection),
and then annually for 5 years
Diagnosis: portal hypertension is diagnosed in children with PVT by
Doppler ultrasound showing splenomegaly and portosystemic
collaterals
There is no validated system with which to assess the severity of
portal hypertension caused by PVT. A suggested approach is as
follows:
Mild or no portal hypertension: non-occlusive thrombus or
occlusion in branch vein with no evidence of splenomegaly or
clinically significant portosystemic shunting/collaterals
Moderate: occlusion of main portal vein or multiple branch veins
with evidence of splenomegaly and/or portosystemic shunting
but without further complications
Severe: moderate plus evidence of complications such as significant
thrombocytopenia, variceal bleeding, and encephalopathy
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in children, the role of screening endoscopy for variceal
identification before a bleed occurs is controversial. After
variceal bleeding, monthly endoscopy to enable treatment
of varices (e.g. by endoscopic variceal ligation) is recom-
mended until varices are obliterated, and then annually
thereafter. Patients may present later with manifestations
of PHT such as coincidental detection of splenomegaly,
thrombocytopenia, or presentation with an acute variceal
bleed. In one case series, PHT was identified at a mean of
5.7 years after the acute event [9]. In other reports, 80%
of patients with PHT presented within the first 3 years of
life [10]. As it is difficult to pinpoint the exact timing of
the development of PVT, the WG recommends screening
for PHT with ultrasound scan as soon as an occlusive
main PVT or portal cavernoma is identified, and then
annually thereafter. If physical examination and ultra-
sound screening in an otherwise stable patient do not sug-
gest PHT after 5 years, it is reasonable to assume that
PHT will not develop.
Outcome after pediatric pulmonary arterial thrombosis (PE)
Chronic thromboembolic pulmonary hypertension
(CTEPH) is a complication of acute symptomatic or
asymptomatic PE, and is diagnosed when the mean pul-
monary artery pressure is ≥ 25 mmHg, the pulmonary
capillary wedge pressure is ≤ 15 mmHg and the pulmo-
nary vascular resistance index is ≥ 3 WU m1 in the pres-
ence of chronic/organized thrombi/emboli after at least
6 months of anticoagulation [11]. It occurs in 0.57–9.1%
of adults after acute PE, and the median time to diagno-
sis is 14.1 months. The exact incidence of pediatric
CTEPH cannot be estimated, and it is probably underdi-
agnosed, owing to a lack of adequate follow-up data
(Table S1).
Although the gold standard for diagnosis of CTEPH is
pulmonary angiography, other non-invasive tests, such as
echocardiography, the 6-min walk test, electrocardiogram,
N-terminal prohormone of brain natriuretic ppetide, and
CT or magnetic resonance angiography, may be helpful
in children who do not routinely undergo cardiac cathe-
terization. A recent single-center study evaluated the
long-term outcomes of PE in 58 children with PE who
were followed for a median duration of 13.3 months.
Echocardiography revealed that right ventricular dilata-
tion was present in 36% and 13% of patients at follow-
up of 6 months and 1 year, respectively.
The severity of CTEPH should be graded as per the
World Health Organization classification [12], and fol-
lowed in conjunction with a pediatric cardiologist/pulmo-
nologist with experience in the management of CTEPH.
As studies in adults suggest that most cases of CTEPH
become apparent within 2 years of the PE [13,14], the
WG recommends that screening for CTEPH after PE
may be performed 6 months after the diagnosis of PE,
and annually thereafter for a period of 2 years
(Table S1).
Outcomes after thrombosis at other rare sites
Pediatric BCS or hepatic venous outflow obstruction is
rare. Possible outcomes after BCS include death, liver
transplantation, persistent chronic liver disease, resolu-
tion of thrombus with anticoagulation or angioplasty,
and persistence of thrombus with resolution of liver syn-
thetic dysfunction and portal hypertensive complica-
tions. Although various indices have been used for
prognostication in adults, the accuracy of these indices
is poor (reference included in the Supporting informa-
tion). None of the indices have been studied or vali-
dated in children with BCS, and we therefore
recommend that patients with BCS should be followed
up by a subspecialist with specific expertise in liver dis-
eases. The WG also felt that recommendations about
outcomes after thrombosis at other rare sites, such as
mesenteric, pelvic or retinal veins, could not be made,
owing to lack of information.
Limitations of recommendations
The purpose of this WG was to develop a systematic
approach to measure outcomes after non-extremity
VTE that are helpful in clinical care and for clinical
trials studies. The overall quality of evidence was ‘2C’,
as the methodological quality of supportive evidence
was low, and there is uncertainty in the estimates of
benefits vs. economic burden of screening tests [15].
The clinical benefit of these screening tools needs fur-
ther validation.
Addendum
M. Rajpurkar reviewed the literature on outcomes after
RVT, PE and thrombosis at other sites, wrote the manu-
script, and coordinated the work with all of the authors.
A. Sharathkumar reviewed the literature on outcomes
after PE, and was involved in manuscript writing. S.
Williams reviewed the literature on outcomes after PVT
and PE, and reviewed and modified the manuscript. K.
Lau reviewed the literature on outcomes after RVT, and
made recommendations on the follow-up of outcomes
after RVT. S. C. Ling reviewed the literature on out-
comes after PVT, and made recommendations on the
follow-up of outcomes after PVT. A. Chan the SSC
Chairman, who initiated the project, supervised all
aspects of the manuscript writing, and made the final
decision(s) on the recommendations. All authors
reviewed and revised the manuscript. Additionally, the
authors would like to thank P. Monagle for his guidance
during the entire project.
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